Skene gland carcinoma is a very rare cancer that starts in small glands near the opening of the urethra. Early symptoms of Skene gland carcinoma can include a lump, pain, bleeding, trouble urinating, or repeated urinary infections. It is most often recognized in adults, usually after menopause, but not everyone will have the same experience. Skene gland carcinoma can be serious because it may spread locally or to other parts of the body, so outlook depends on the stage at diagnosis. Treatment usually involves surgery and may also include radiation therapy, chemotherapy, or both.
How many people live with Skene gland carcinoma?
Global and U.S. prevalence estimates for Skene gland carcinoma are not consistently reported by a single authoritative source. It is considered exceptionally rare and is described mainly in single published cases and very small case series, so no reliable estimate is available for how many people are living with it worldwide or in the United States.
Overview
Skene gland carcinomaSymptoms
Skene gland carcinoma can cause a painful lump near the urethra, bleeding, pain with sex, or trouble peeing. Early symptoms of Skene gland carcinoma can look like a urinary tract infection, but some people also notice ongoing pelvic pain or blood in the urine.
Outlook and prognosis
In Skene gland carcinoma, outlook depends mainly on how early it is found and whether it has spread. When it is small and localized, treatment often works well. Cancers found later may need more treatment and closer follow-up.
Causes and risk factors
The exact cause of Skene gland carcinoma is unclear. Risk may rise with older age, long-term irritation or inflammation in the urethral area, and possibly hormone-related or genetic factors. Some cases develop without any clear risk factor.
Genetic influences
Genetics are not known to play a major role in Skene gland carcinoma; most cases appear sporadic. Because it is so rare, no clear inherited genetic pattern or common mutation has been confirmed.
Diagnosis
Skene gland carcinoma is diagnosed with a pelvic exam and imaging to check the area and nearby tissues. A biopsy confirms the diagnosis of Skene gland carcinoma by showing cancer cells under the microscope.
Treatment and drugs
Treatment for Skene gland carcinoma often combines surgery with imaging-guided planning. Some also need radiation or chemotherapy, depending on the tumor’s size, spread, and nearby organs. Follow-up visits help watch for recurrence and manage urinary or pelvic symptoms.
Symptoms
Skene gland carcinoma often shows up as urinary problems or a tender lump near the opening where urine leaves the body. Some people also notice spotting, discharge, or pain in the pelvis or during sex, and these problems can be mistaken for a urinary tract infection, a cyst, or irritation. The early symptoms of Skene gland carcinoma can be subtle, and symptoms vary from person to person and can change over time.
Burning, stinging, or discomfort when passing urine is common. It can feel a lot like a urinary tract infection, especially if the irritation keeps returning or does not improve as expected.
Some people feel the need to urinate more often or more urgently, even when the bladder is not very full. Day to day, this can mean more trips to the bathroom and trouble getting through a meeting, car ride, or full night of sleep.
A growth near the urethra can partly block urine flow. This may cause a weak stream, trouble starting, dribbling, or a feeling that the bladder does not empty fully.
Some people notice a small lump, fullness, or swelling near the urethral opening or the front wall of the vagina. It may be painless at first or become tender over time.
How people usually first notice Skene gland carcinoma?
Skene gland carcinoma is usually first noticed when someone develops a new lump, swelling, or tenderness near the urethral opening, the small tube where urine leaves the body, and it may feel like something is “not right” in that area rather than causing dramatic symptoms at first. For many people, the first signs of Skene gland carcinoma are bleeding, pain during urination, burning, repeated urinary symptoms that do not settle, or discomfort during sex, although these problems are much more often caused by noncancerous conditions. Because this cancer is very rare, how Skene gland carcinoma is first noticed can vary, but a persistent mass or symptoms that keep coming back are what usually lead someone to seek care and get examined.
Types of Skene gland carcinoma
Skene gland carcinoma can show up in a few different symptom patterns, and early on it may be easy to mistake for a urinary tract or urethral problem. Symptoms don’t always look the same for everyone. In many living with Skene gland carcinoma, the main differences come from whether the tumor is causing irritation near the urethra, forming a noticeable lump, or spreading beyond the area. Early symptoms of Skene gland carcinoma often involve urinary changes or discomfort rather than a dramatic new symptom.
Urinary symptoms
Many people with Skene gland carcinoma notice burning with urination, trouble starting the stream, or feeling like they need to go often. Some may also have weak flow or a sense that the bladder does not empty fully.
Lump or pressure
Some living with Skene gland carcinoma feel a small mass near the urethral opening or notice tenderness in that area. For many, this can mean pressure, discomfort when sitting, or pain during sex.
Bleeding or discharge
Another common pattern is spotting, blood in the urine, or unusual discharge from the area near the urethra. These symptoms can be intermittent at first, which sometimes delays recognition.
Advanced symptoms
If Skene gland carcinoma grows into nearby tissues or spreads, pain can become more constant and urinary blockage may get worse. Some people may also develop pelvic pain, fatigue, or unexplained weight loss.
Can I slow down the onset of symptoms?
For Skene gland carcinoma, there is no good evidence that lifestyle changes or medical treatment can meaningfully delay when symptoms begin. Because this cancer is very rare, research has not identified proven risk-lowering steps for it, and there are no well-established screening tests or preventive medicines for people without symptoms. The most helpful step is to get new urinary problems, pain, bleeding, or a new lump near the opening where urine comes out checked early, which cannot prevent the cancer but may help it be found and treated sooner.
What genetics can tell you about symptoms
Because Skene gland carcinoma is very rare, genetics cannot usually predict with confidence which symptoms someone will have, how severe they will be, or exactly when they will start. In most people, symptoms are driven more by where the tumor is growing and how far it has spread, which can lead to changes like a lump near the urethra, pain, bleeding, or trouble urinating. Genetic testing may sometimes find changes in tumor cells that help doctors understand the cancer better or guide treatment, but this is not yet a reliable way to forecast day-to-day symptoms for most people living with this condition.
Causes and risk factors
Because so few cases have been studied, the exact causes and risk factors for Skene gland carcinoma are not well understood. Most reported cases have been in older adults, so age may raise risk. Long-term inflammation, repeated infection, or blockage in the gland or nearby urethra may also play a part, but the evidence is limited. No specific inherited gene has been clearly linked to Skene gland carcinoma, and lifestyle or environmental triggers have not been proven. Knowing the risks can help you feel more in control, but many people who develop it have no clear risk factor.
What are the most common causes or risk factors?
For Skene gland carcinoma, the exact cause is not known, and no inherited gene change has been clearly proven to raise the risk. Because this cancer is very rare, doctors mainly know that it tends to happen in older adults and may be more likely in people with long-term irritation near the urine tube, such as repeated infections, ongoing swelling, or a urethral diverticulum, which is a small pouch next to the tube that carries urine out of the body. There is no strong evidence that common lifestyle factors are a main cause.
Environmental and biological risk factors
Because Skene gland carcinoma is very rare, the best-known risk factors for Skene gland carcinoma are still not fully mapped out. Most of what doctors know comes from small case reports rather than large studies. Researchers are still exploring how outside influences interact with our inner biology. For now, older age and long-standing local inflammation are the main factors sometimes linked with this cancer.
Most reported cases have been in older adults, often after menopause. Age does not directly cause cancer, but the chance of abnormal cell changes in this area appears to rise later in life.
Long-term irritation around the urethra and nearby glands may raise risk over time. Repeated infection or ongoing inflammation can keep cells under stress, which may make abnormal changes more likely.
Paraurethral cysts, blocked ducts, or nearby pockets such as a urethral diverticulum can trap fluid and promote lasting irritation. In rare reports, Skene gland carcinoma has been found in tissue affected by these problems, although the link is not firmly proven.
No specific environmental exposure has been clearly shown to cause Skene gland carcinoma. Because this cancer is so rare, links with toxins, radiation, or other outside exposures remain uncertain.
Genetic risk factors
Skene gland carcinoma is so rare that no single inherited gene change has been confirmed as its cause. Many living with this cancer do not have a clear family pattern. Because there are so few studied cases, the genetic risk factors for Skene gland carcinoma are still not well defined. Most of what doctors know comes from broader cancer genetics rather than disease-specific data.
No clear gene: No inherited gene change has been proven to directly cause Skene gland carcinoma. Because this cancer is extremely rare, most information comes from isolated case reports rather than large genetic studies.
Family history: A strong family history of cancers that cluster in families can sometimes point to an inherited cancer tendency, but this has not been linked specifically to Skene gland carcinoma. This is more of a clue to look closer than a known cause on its own.
Inherited syndromes: Rare inherited cancer syndromes may raise the chance of several cancers in the body, yet none is a well-established genetic cause of Skene gland carcinoma. In some cases, genetic testing can give a clearer picture of your personal risk.
Tumor DNA changes: Genetic changes may be found in the cancer cells themselves, but these are usually acquired in the tumor and are not the same as inherited risk. A tumor finding does not automatically mean close relatives are more likely to develop the same cancer.
Lifestyle risk factors
Because Skene gland carcinoma is extremely rare, its lifestyle risk factors have not been defined as clearly as they have for more common cancers. Still, some habits that raise the risk of urogenital and other cancers may also matter here, especially those linked to chronic inflammation, hormonal changes, and delayed diagnosis. When people ask about lifestyle risk factors for Skene gland carcinoma, the most honest answer is that evidence is limited, but several modifiable factors may still be relevant.
Tobacco use is the lifestyle factor most plausibly linked to a higher cancer risk in this area, based on what is known from other urinary and genital tract cancers. Smoking can promote DNA damage and chronic local irritation, which may contribute to malignant change. Quitting smoking may help lower overall cancer risk and support treatment recovery.
Obesity may raise cancer risk through chronic inflammation, altered estrogen signaling, and insulin-related growth pathways. These biologic effects are not specific to the Skene glands, but they are relevant when thinking about how lifestyle affects Skene gland carcinoma. Keeping weight in a healthy range may help reduce these cancer-promoting signals.
Physical inactivity often worsens weight gain, insulin resistance, and systemic inflammation, all of which can support cancer development over time. No direct study has proved this specifically for Skene gland carcinoma, but regular exercise is a reasonable risk-reduction habit. Activity also helps maintain fitness before and after cancer treatment.
Heavy alcohol intake is linked to several cancers and may contribute through inflammation, oxidative stress, and impaired immune defenses. A direct connection to Skene gland carcinoma has not been established, but limiting alcohol is sensible when overall cancer risk is the concern. Lower intake may also improve general health during treatment.
Risk prevention
Because Skene gland carcinoma is very rare, there is no proven way to fully prevent it. For many, prevention is really about lowering risk where possible and getting urinary, pelvic, or vaginal symptoms checked early instead of waiting to see if they pass. Prevention is about lowering risk, not eliminating it completely. This can matter if symptoms like pain with urination, a new lump near the urethra, or bleeding appear and could otherwise be mistaken for a more common problem.
Early medical attention for urinary burning, bleeding, pelvic pain, or a lump near the urethra may help find problems sooner. Because the early symptoms of Skene gland carcinoma can overlap with infection or irritation, it is wise to get persistent or unusual changes checked.
Recurrent urinary or gland infections should be assessed and treated rather than repeatedly self-managing at home. This may reduce ongoing inflammation, which is a general cancer risk factor in some tissues, even though a direct prevention method for Skene gland carcinoma is not established.
Routine gynecologic and primary care visits can help pick up changes that might otherwise be missed. Prevention works best when combined with regular check-ups.
A cyst, swelling, or tenderness near the vaginal opening or urethra that keeps coming back deserves follow-up. In some cases, imaging, drainage, or biopsy may be needed to make sure a benign problem is not hiding something more serious.
Can you prevent Skene gland carcinoma?
There is no known sure way to prevent Skene gland carcinoma, and because it is very rare, no proven prevention steps have been established. In general, avoiding smoking and getting ongoing symptoms such as a lump, pain, bleeding, or trouble passing urine checked promptly may help support overall health. Regular pelvic exams may help find problems earlier, but that is not the same as preventing this cancer.
Transmission
Skene gland carcinoma is not infectious, and it cannot be passed from one person to another through sex, kissing, touching, shared toilets, or other everyday contact. If you are wondering whether Skene gland carcinoma is contagious, the answer is no.
This cancer develops when cells in the Skene gland start growing out of control, rather than from a germ that spreads between people. There is also no well-established pattern showing that Skene gland carcinoma is usually inherited from a parent, although a clinician may ask about your family history of cancer as part of the overall evaluation.
When to test your genes
For Skene gland carcinoma, gene testing is not routine for early detection because this cancer is very rare and no standard inherited screening panel exists. It may be worth discussing if you have a strong personal or family history of related cancers, or if tumor testing could guide treatment choices.
Diagnosis
Skene gland carcinoma is usually diagnosed after symptoms lead to a pelvic exam and testing, rather than being found on a routine screen. Because this cancer is rare and can mimic more common problems such as a urethral cyst, urinary infection, or gland blockage, the diagnosis may take time. It’s natural to worry when symptoms don’t have a clear explanation. Early symptoms of Skene gland carcinoma can include a lump near the urethral opening, pain, bleeding, or trouble urinating.
Doctors usually begin by asking about urinary symptoms, bleeding, pain during sex, and any new lump or swelling near the vaginal opening. A detailed history helps show how long symptoms have been present and whether they fit a more common condition or raise concern for cancer.
A clinician examines the area around the urethra and front wall of the vagina to look for a mass, tenderness, skin changes, or discharge. This exam can help identify where the growth is starting and whether nearby tissues may be involved.
Urinalysis and other lab tests may help rule out common conditions such as infection or blood in the urine from another cause. These tests do not confirm cancer, but they can help explain symptoms and guide the next step.
Your provider may suggest pelvic MRI or CT imaging to look closer at the size and exact location of the tumor. These scans also help assess nearby structures, including the urethra, bladder, and lymph nodes, as part of the diagnosis of Skene gland carcinoma.
How is Skene gland carcinoma diagnosed?
Skene gland carcinoma is usually diagnosed after a doctor reviews symptoms, does a pelvic exam, and checks any lump or sore area near the opening of the urethra, the tube that carries urine out of the body. Scans such as ultrasound, MRI, or CT can help show the size of the growth and whether nearby tissues are involved, but the diagnosis is confirmed with a biopsy, which means taking a small tissue sample to look at under a microscope. Genetic testing is not usually the main part of diagnosis for this rare cancer.
Stages of Skene gland carcinoma
Skene gland carcinoma does not have defined progression stages. This is mainly because it is a very rare cancer, so there is no widely used stage-by-stage course that is specific to the Skene glands, and doctors usually judge it by how much the tumor has grown and whether it has spread. Doctors usually start with a conversation about symptoms, which can include a lump near the urethra, pain, bleeding, trouble urinating, or other early symptoms of Skene gland carcinoma, followed by a pelvic exam and imaging tests. A biopsy is usually needed to confirm the diagnosis, and ongoing follow-up often focuses on checking the tumor site and looking for any local spread or recurrence.
Outlook and prognosis
The outlook for Skene gland carcinoma is uncertain because it is extremely rare, so prognosis is based mostly on individual case reports rather than large studies. In general, outcomes appear better when the tumor is found early and completely removed, while prognosis is worse with local invasion, lymph node involvement, or distant metastases. Reported treatment often includes surgery, sometimes combined with radiation therapy or chemotherapy, and long-term follow-up is important because recurrence can occur. Mortality data are not well established, but deaths have been reported in advanced or metastatic cases. Because so few cases exist, a person’s prognosis depends heavily on tumor stage, pathology, response to treatment, and care from an experienced multidisciplinary cancer team.
Long-term effects
Skene gland carcinoma is rare, so the long-term outlook can vary a lot from one person to another. For many, this can mean living with uncertainty about whether the cancer will stay controlled, come back locally, or spread to nearby tissues or farther parts of the body. In medical terms, these are sometimes called late effects or chronic symptoms. Long-term effects often depend on the stage at diagnosis, whether treatment fully removed or controlled the tumor, and whether the cancer behaves more aggressively over time.
One of the main long-term concerns with Skene gland carcinoma is recurrence, meaning the cancer comes back after treatment. This may happen in the same area near the urethra or in nearby pelvic tissues, sometimes months or years later.
Some people have lasting urinary symptoms such as burning, urgency, a weak stream, or trouble fully emptying the bladder. These problems can come from the tumor itself, scarring after surgery, or effects of radiation on nearby tissues.
Ongoing pain, pressure, or tenderness in the vulvar or pelvic area can affect daily comfort, sitting, exercise, and sex. Many living with Skene gland carcinoma notice these symptoms more if treatment involved surgery or radiation near sensitive tissue.
Treatment may lead to vaginal dryness, pain with sex, reduced arousal, or body-image changes that last well beyond the first recovery period. For many, symptoms improve with time, but some long-term effects can persist.
How is it to live with Skene gland carcinoma?
Living with Skene gland carcinoma can be physically and emotionally draining because symptoms often affect very private, everyday functions like urination, sitting comfortably, sexual activity, and feeling at ease in your own body. Many people living with this rare cancer may also be coping with appointments, scans, surgery, and sometimes radiation or other treatments, which can disrupt work, sleep, intimacy, and routines. Because the Skene glands sit near the urethra, some may find that pain, urinary symptoms, or worry about recurrence become a constant background stress, but support from a cancer care team, pelvic health specialists, and trusted loved ones can make daily life feel more manageable. It can affect people around you too, as partners and family members often take on caregiving, practical tasks, and emotional support, so open conversation and shared support matter for everyone involved.
Treatment and drugs
Skene gland carcinoma is usually treated much like other cancers near the urethra and vulva, with surgery often being the main treatment if the tumor can be removed. Depending on the size of the cancer, whether it has spread, and a person’s overall health, doctors may also recommend radiation therapy, chemotherapy, or both, especially when surgery alone is not enough.
Treatment often looks different for each person, because this is a rare cancer and care is usually tailored to the exact location and stage of the tumor. Alongside medical treatment, lifestyle choices play a role, and many people also need help with pain control, urinary symptoms, wound care, and regular follow-up visits to check for recurrence and manage side effects.
Can you cure Skene gland carcinoma?
Skene gland carcinoma is a very rare cancer, and there is no guaranteed cure for everyone. If it is found early, treatment such as surgery, and sometimes radiation or drug treatment, may remove the cancer and can lead to long-term control or cure in some people. When it has spread or comes back, treatment usually focuses on shrinking the cancer, slowing it down, and easing symptoms.
Non-drug treatment
For many living with Skene gland carcinoma, treatment often centers on procedures and supportive care rather than medicines alone. Because this cancer is rare and sits close to the urethra and surrounding pelvic tissues, care is usually planned by a team with experience in gynecologic, urologic, or pelvic cancers. Non-drug treatments may be used to remove or control the tumor, ease urinary or pelvic symptoms, and support recovery. Not every approach works the same way, and the best plan depends on the tumor size, spread, and your overall health.
Surgery is often the main non-drug treatment for Skene gland carcinoma, especially when the tumor appears localized. The goal is to remove the cancer while protecting urination and nearby pelvic structures as much as possible. Depending on the extent, this may involve a smaller local operation or a more complex pelvic procedure.
Radiation uses targeted high-energy beams to treat cancer in the gland area and nearby tissues. It may be used after surgery, instead of surgery for some people, or to help control pain, bleeding, or pressure symptoms. For some, treatment begins not at the pharmacy, but in a radiation center over several scheduled visits.
If scans or the exam suggest spread, doctors may remove or sample nearby lymph nodes to see whether cancer cells have traveled. This can help guide treatment choices and give a clearer idea of stage. It is not needed for everyone with Skene gland carcinoma.
Some people with Skene gland carcinoma have burning, blockage, dribbling, or trouble emptying the bladder before or after treatment. Procedures such as catheter drainage or other urinary support can help protect the kidneys and make day-to-day life easier. This can be especially important when early symptoms of Skene gland carcinoma include changes in urination.
Your genes may have an impact on how drugs work for you
Because Skene gland carcinoma is very rare, there is no well-established, routine gene-based guide for choosing medicines for it. Even so, inherited differences between people can affect how the body handles some cancer treatments, which may change how well a medicine works or how strongly side effects such as tiredness, nausea, or low blood counts show up. In some cases, the care team may use testing of the cancer itself, or sometimes broader genetic testing, to help guide treatment choices, but this is not a standard step for everyone living with this cancer.
Pharmacological treatments
Drug treatment for Skene gland carcinoma is usually individualized because this cancer is very rare, and there is no single standard medicine used for everyone. When medicines are needed, they are most often used for cancer that has spread, come back, or cannot be fully treated with surgery or radiation, and the drug choices are usually borrowed from treatments for urethral or other nearby gland-forming cancers. Not everyone responds to the same medication in the same way.
Cisplatin and carboplatin are common backbone chemotherapy drugs for advanced or recurrent Skene gland carcinoma. They damage cancer cells and are often paired with another medicine rather than used alone. Kidney function, hearing, nerve symptoms, and blood counts usually need close monitoring.
Paclitaxel, and sometimes docetaxel, may be combined with a platinum drug when doctors want a broader chemotherapy approach. These medicines can slow cancer growth, but they may also cause numbness in the hands or feet, hair loss, and low blood counts. In some people, this combination is considered when looking for treatment options for advanced Skene gland carcinoma.
5-fluorouracil, often called 5-FU, may be used in some treatment plans, sometimes with cisplatin or mitomycin depending on the cancer pattern and overall treatment goal. This approach is more often borrowed from related urethral cancer care than from studies specific to Skene gland carcinoma. Mouth sores, diarrhea, and low blood counts can happen and need watching.
Gemcitabine is another chemotherapy drug that may be used, especially when doctors are choosing from regimens used in urinary tract or pelvic cancers. It is sometimes paired with cisplatin or carboplatin in people who need systemic treatment. Fatigue, infection risk, and low blood counts are common concerns during treatment.
Genetic influences
When someone is diagnosed with Skene gland carcinoma, it is understandable to wonder whether close relatives are also at risk. Right now, there is no well-established inherited gene change known to cause most cases of Skene gland carcinoma, so genetic testing for Skene gland carcinoma is not routine in the way it is for some other cancers. In many living with this cancer, the gene changes that matter are thought to develop in the tumor during life rather than being passed down at birth. Family history is one of the strongest clues to a genetic influence. If there is a strong family pattern of early, rare, or multiple cancers, a doctor may suggest genetic counseling to look for a broader inherited cancer syndrome, but evidence specific to Skene gland carcinoma is still limited.
Is Skene gland carcinoma genetic?
Genetics are not known to play a major role in Skene gland carcinoma; most cases appear sporadic. Because it is so rare, no clear inherited genetic pattern or common mutation has been confirmed.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a normal part of being human and are common across the general population. Most do not have a direct effect on health and simply add to natural human diversity. For many genes, having a variant associated with a condition suggests a possible link rather than a certain diagnosis, especially when multiple genes and environmental factors play a part. In some situations, though, a single well-understood variant in a specific gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
Treatment for Skene gland carcinoma is usually guided first by where the cancer is, how far it has spread, and whether surgery is possible. Because this cancer is very rare, inherited genetic results do not usually decide the standard drugs used, and doctors often have to draw on experience from similar cancers in nearby tissues. In some advanced or recurrent cases, testing the tumor’s genes may occasionally help look for changes that could support the use of a targeted drug or immunotherapy, although this does not help everyone. Genetics is only one factor, and many people with Skene gland carcinoma still have treatment plans based mainly on surgery, radiation, and sometimes chemotherapy. Separate from the tumor itself, your own genes can sometimes affect how your body handles certain cancer medicines, which may influence side effects or dosing, but this kind of drug-response testing is not yet a routine part of care for Skene gland carcinoma. If options feel limited, it is reasonable to ask whether genetic testing for Skene gland carcinoma could add useful information for your treatment plan.
Interactions with other conditions
Skene gland carcinoma can affect daily life by causing symptoms that look a lot like more common urinary problems, such as burning, pelvic pain, trouble passing urine, or repeated infections. Because this cancer is very rare, doctors do not have strong evidence that it regularly occurs alongside any one specific disease, but its symptoms often overlap with urinary tract infections, urethral diverticula, and other nearby cancers, which can delay diagnosis. Doctors call it a comorbidity when two conditions occur together. For many living with Skene gland carcinoma, another bladder or urethral problem can make symptoms feel more intense, and the early symptoms of Skene gland carcinoma may be mistaken for an infection that keeps coming back. If someone already has urinary blockage, chronic irritation, or another pelvic condition, careful evaluation is important so treatment addresses the full picture rather than just one likely cause.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Skene gland carcinoma?
Similar symptoms can also happen with a urinary tract infection, a blocked or infected Skene gland, a urethral diverticulum, which is a small pouch beside the tube that carries urine out of the body, or other growths near the urethra such as a urethral caruncle or urethral cancer. These problems can all cause pain, a lump near the urine opening, bleeding, or trouble passing urine, so doctors usually need an exam and often a biopsy, meaning a small tissue sample, to tell them apart.
History
People living with Skene gland carcinoma often reach a diagnosis only after a stretch of confusing symptoms, such as a lump near the urethra, pain, bleeding, or trouble passing urine. Because this cancer is so uncommon, it has a shorter and more fragmented medical history than many other cancers, and for many years it was recognized mainly through individual case reports rather than large studies.
Since the earliest days of medicine, efforts have been made to understand diseases of the tissues around the female urethra, but Skene gland carcinoma was not clearly separated from other nearby cancers at first. Early doctors sometimes grouped these tumors with cancers of the urethra, vaginal wall, or surrounding glands because the area is small and the tissues lie very close together. That meant some cases were probably described under different names, and some may have been missed entirely.
As pathology improved, doctors became better able to tell where a tumor started by looking closely at the cells under the microscope. This helped identify Skene gland carcinoma as a distinct, though very rare, cancer arising from the Skene glands, which sit near the opening of the urethra. Over time, descriptions became more precise, and reports began to note patterns such as local swelling, urinary symptoms, and in some cases spread to nearby tissues or lymph nodes.
In more recent decades, imaging scans, improved biopsy methods, and more careful tissue testing have helped doctors recognize Skene gland carcinoma with greater accuracy. Even so, much of what is known still comes from small numbers of patients, so treatment approaches have often been guided by experience with similar cancers in the same area. Knowing the condition’s history helps explain why there is still limited information about early symptoms of Skene gland carcinoma, long-term outcomes, and the best treatment plan for every situation. Even with these limits, today’s understanding is far clearer than it was in the past, and diagnosis is generally more precise than it used to be.